Display Settings:

Format

Send to:

Choose Destination
    Semin Hematol. 2004 Jan;41(1 Suppl 1):140-4.

    Thromboelastography and recombinant factor VIIa-hemophilia and beyond.

    Source

    Center for Hemophilia and Thrombosis, Department of Clinical Biochemistry, Aarhus University Hospital, Skejby Hospital, Arhaus, Denmark.

    Abstract

    Thromboelastography (TEG), which records the continuous profiles of whole blood (WB) coagulation, can be used to evaluate the effects of hemostatic agents, such as recombinant factor VII (rFVIIa). Our group has developed a revised TEG model, involving activation with minute amounts of tissue factor and subsequent signal processing, and has used this method to evaluate the effects of rFVIIa both in patients with hemophilia and in those receiving vitamin K antagonist (VKA) thromboprophylaxis. We review the early results of our investigations, which suggest that, in clinical situations where rFVIIa has shown benefit, the changes in the profiles obtained by TEG recording appear to correlate with the clinical outcome.

    PMID:
    14872435
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Elsevier Science

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk